Cassava Sciences Inc vs Liberty Global Ltd Class C — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Liberty Global Ltd Class C trades at $8.43 (market cap $3.06B). The key difference: Liberty Global Ltd Class C is far larger — about 77.7× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Liberty Global Ltd Class C for 21 Days on average.
| FLNA | LBTYK | |
|---|---|---|
Market Cap | $39.40M | $3.06B |
Volume | 759,018 | 2,508,956 |
Sector | Health | Media |
52-Week High | $4.64 | $12.67 |
52-Week Low | $0.68 | $8.75 |
Typical Hold Time | 37 Days | 21 Days |
Enterprise Value | -$43.28M | $9.72B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Liberty Global (LBTYK) trades at $8.41, down 5.72% on the day and near 52-week lows. The stock shows bearish technical signals with negative moving averages and oscillators, though RSI indicates oversold conditions. Fundamentally, the company reported a net loss of $7.14B in 2025 despite $4.88B revenue, but cash flow remains positive at $264.8M. Recent developments include the VodafoneZiggo acquisition and preparations for Ziggo Group's 2027 listing.
The outlook remains challenging with persistent losses and bearish technicals, but analyst consensus is bullish with a $12.67 price target. Key opportunities include Ziggo Group's planned spin-off and AI partnerships, while risks involve execution on profitability and competitive pressures in telecom markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →